机构：[1]Department of Basic Medicine, Inner Mongolia Medical University, Jinshan Development Zone, Huhhot 010110, China.[2]Department of Orthopaedic Surgery and Biomedical Engineering, The University of Tennessee Health Science Center, Memphis, TN 38103, USA.[3]Research Center, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang 050011, China.河北医科大学第四医院[4]Beijing Cancer Hospital and Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, China.[5]Center of Integrative Research, The First Hospital of Qiqihar, Qiqihar 161005, China.[6]Affiliated Qiqihar Hospital, Southern Medical University, Qiqihar 161007, China.[7]Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China.[8]School of Chinese Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, China.[9]Heilongjiang Academy of Traditional Chinese Medicine, 41 Xiangshun St, Xiangfang District, Harbin 150040, China.[10]Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY 10032, USA.[11]Department of Acute and Tertiary Care, University of Tennessee Health Science Center, Memphis, TN 38103, USA.[12]Health Outcomes and Policy Research, Department of Clinical Pharmacy and Translational Science, University of Tennessee College of Pharmacy, 881 Madison Avenue, Room 219, Memphis, TN 38163, USA.[13]Research Service, Memphis VA Medical Center, 1030 Jefferson Avenue, Memphis, TN 38104, USA.
Whether smokers respond to anti-cancer drugs differently than non-smokers remains controversial. The objective of this study is to explore whether the better response of the smokers is specific to therapy of anti-PD-1/PD-L1, anti-checkpoint inhibitor, individual drugs on the cell surface, or lung cancer. Our results showed that among all non-small cell lung cancer (NSCLC) patients, when the data from anti-PD-1/PD-L1, anti-CTLA-4, and anti-MUC1 drugs are combined, the mean hazard ratios (HR) of smokers and non-smokers were 0.751 and 1.016, respectively. A meta-analysis with a fixed effect (FE) model indicated that the smokers have an HR value of 0.023 lower than that of the non-smokers. A stratified subgroup meta-analysis indicated that when treated with anti-CTLA-4 drugs, smokers had reduced HR values of 0.152 and 0.165 on average and FE model meta-analysis, respectively. When treated with an anti-MUC1 drug, smokers had reduced HR values of 1.563 and 0.645, on average and FE model meta-analysis, respectively. When treated with a combination of nivolumab and ipilimumab drugs, smokers had, on average, reduced HR and FE model meta-analysis values (0.257 and 0.141), respectively. Smoking is a clinical response predictor for anti-PD/PD-L1 monotherapy or first-line treatment in lung, urothelial carcinoma, and head and neck cancer. Smokers treated with other drugs have shown worse responses in comparison to non-smokers. These data suggest that, along with the progress in the development of new drugs for cancer, drugs acting on specific genotypes of smokers likely will arise.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2021]版：
大类|2 区医学
小类|2 区卫生保健与服务2 区医学：内科
最新[2025]版：
无
JCR分区：
出版当年[2021]版：
Q2HEALTH CARE SCIENCES & SERVICESQ2MEDICINE, GENERAL & INTERNAL
最新[2023]版：
Q1MEDICINE, GENERAL & INTERNALQ2HEALTH CARE SCIENCES & SERVICES
第一作者机构：[1]Department of Basic Medicine, Inner Mongolia Medical University, Jinshan Development Zone, Huhhot 010110, China.[2]Department of Orthopaedic Surgery and Biomedical Engineering, The University of Tennessee Health Science Center, Memphis, TN 38103, USA.
共同第一作者：
通讯作者：
通讯机构：[2]Department of Orthopaedic Surgery and Biomedical Engineering, The University of Tennessee Health Science Center, Memphis, TN 38103, USA.[13]Research Service, Memphis VA Medical Center, 1030 Jefferson Avenue, Memphis, TN 38104, USA.
推荐引用方式(GB/T 7714)：
Wang Lishi,Liu Fengxia,Li Jing,et al.From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?[J].JOURNAL OF PERSONALIZED MEDICINE.2021,11(9):doi:10.3390/jpm11090914.
APA：
Wang Lishi,Liu Fengxia,Li Jing,Ma Li,Feng Helin...&Ji Jiafu.(2021).From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?.JOURNAL OF PERSONALIZED MEDICINE,11,(9)
MLA：
Wang Lishi,et al."From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?".JOURNAL OF PERSONALIZED MEDICINE 11..9(2021)
